Patents

US 12758583 B2: Targetable immune checkpoint for immunotherapy

Granted
2026-10-13
Filed
2023-01-12 application 18153426
Type
Utility · 21 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present disclosure relates to the field of T cell-based immunotherapy to promote anticancer effector functions.

Source: PTBLXML, file of 2026-10-13 (ipgb20261013.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Ohio State Innovation Foundation 733 patentsUS company or organizationColumbus, OHOHIO STATE INNOVATION FOUNDATION Nonprofit EXACT high confidence: identical full name and statePTBLXML, file of 2026-10-13

Inventors

InventorPlacePatentsPerson pageSource
Haitao WenColumbus, OHPTBLXML, file of 2026-10-13

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K35/17PTBLXML, file of 2026-10-13
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P35/00PTBLXML, file of 2026-10-13
C07KPeptidesC07K16/2896PTBLXML, file of 2026-10-13

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

No recorded assignments or security interests on file for this patent.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.